Gland PharmaNSE:GLAND -0.49%83 Days Payable is 128.68 as of Mar. 2026, which is 12% above its 10-year median of 115.14. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review. Among 920 Drug Manufacturers companies, Gland Pharma ranks better than 71.96% on this metric.
The historical rank and industry rank for Gland Pharma's Days Payable or its related term are showing as below:
NSE:GLAND'
s Days Payable Range Over the Past 10 Years
Min: 74.34 Med: 115.14 Max: 161.2
Current: 139.83
During the past 9 years, Gland Pharma's highest Days Payable was 161.20. The lowest was 74.34. And the median was 115.14.
NSE:GLAND's Days Payable is ranked better than 71.96% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:GLAND: 139.83
Gland Pharma's Days Payable
declined
from Mar. 2025 (153.42) to Mar. 2026 (128.68).
It may suggest that Gland Pharmaaccelerated paying its suppliers.
Gland Pharma Days Payable Related Terms
Gland Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gland Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a Days Payable of 128.68 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gland Pharma and its competitors. This is 12% above median its historical median of 115.14. Over the past decade, Gland Pharma's Days Payable has ranged from 74.34 to 161.20. According to the industry distribution chart, Gland Pharma ranks #258 out of 920 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Gland Pharma's Days Payable too high?
Gland Pharma's current Days Payable of 128.68 is 12% above median its 10-year median of 115.14. Over the past 10 years, this metric has ranged from a low of 74.34 to a high of 161.20. The Drug Manufacturers industry median Days Payable is 90.84. Gland Pharma's value of 128.68 is 41.7% above this industry median. Based on the distribution chart, Gland Pharma ranks #258 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #258 out of 920 companies for Days Payable. This puts Gland Pharma in the upper half of its industry. The industry median Days Payable is 90.84. Gland Pharma's value of 128.68 is 41.7% above this benchmark. Historically, Gland Pharma's own Days Payable has ranged from 74.34 to 161.20 over the past decade. While the company's 10-year median is 115.14 vs. the industry median of 90.84, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Days Payable of 128.68 is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Days Payable is 128.68, which is 12% above median its own 10-year median of 115.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current Days Payable is 128.68, which is 12% above median its 10-year median of 115.14 and 41.7% above the Drug Manufacturers industry median of 90.84. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Days Payable is 128.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
Days Payable: 128.68 (12% above median its 10-year median of 115.14)
GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
Industry Position: 41.7% above the Drug Manufacturers median (#258 of 920)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
